

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

217186Orig1s000

NON-CLINICAL REVIEW(S)

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION

Application number: 217186
Supporting document: 1
Applicant's letter date: August 31, 2022
CDER stamp date: August 31, 2022
Product: Crexont
Indication: Parkinson's Disease
Applicant: Impax Laboratories, LLC
Review Division: DPTN
Reviewer: LuAnn McKinney, DVM, DACVP
Acting Team Leader: David Carbone, PhD
Supervisor: Lois Freed, PhD
Division Director: Lois Freed, PhD
Project Manager: Stacy Metz, PharmD

TABLE OF CONTENTS

1	NONCLINICAL SUMMARY	3
----------	----------------------------------	----------

1 Nonclinical Summary

Crexont (IPX203) is a 1:4 fixed dose combination of carbidopa (CD) and levodopa (LD) formulated as extended-release capsules intended for the treatment of Parkinson's disease. NDA 217186 was submitted under the 505(b)(2) pathway, with reliance upon the previous findings of safety and effectiveness for the listed drug, Sinemet, to support the NDA. The sponsor was advised during a Pre-NDA meeting (IND 122793; March 4, 2022) that, if an adequate bridge was established to the intended listed drug and that no safety concerns were identified, additional nonclinical studies would not be needed for the NDA.

Based on discussions with the clinical pharmacology team, plasma carbidopa exposure in patients administered the maximum recommended human dose (MRHD) of Crexont ((b) (4) LD) exceed that of Sinemet. The safety of the higher CD exposure is to be assessed in clinical trials; therefore, no additional nonclinical data are needed to support the proposed MRHD or the NDA.

Approval of Crexont is deferred to the clinical team.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LUANN MCKINNEY
05/30/2023 01:38:55 PM

LOIS M FREED
05/30/2023 01:40:52 PM